scholarly journals Nalidixic acid resistance predicting reduced ciprofloxacin susceptibility of Salmonella enterica serovar Typhi

2012 ◽  
Vol 2 ◽  
pp. S585-S587 ◽  
Author(s):  
Shyamapada Mandal ◽  
Manisha DebMandal ◽  
Nishith Kumar Pal
Keyword(s):  
Nalidixic Acid ◽  
Salmonella Enterica ◽  
Acid Resistance ◽  
Salmonella Enterica Serovar Typhi ◽  
Nalidixic Acid Resistance

scholarly journals Antibiogram of Salmonella Spp Isolates in Kathmandu, Nepal

2018 ◽  
Vol 5 (2) ◽  
pp. 22-25 ◽  
Author(s):  
Damodar Gajurel ◽  
Rabi Prakash Sharma ◽  
Krishna Dhungana ◽  
Samir Neupane ◽  
Kamal Lamsal ◽  
...  
Keyword(s):  
Nalidixic Acid ◽  
Salmonella Enterica ◽  
Acid Resistance ◽  
Asian Countries ◽  
Medical Sciences ◽  
Salmonella Spp ◽  
Salmonella Enterica Serovar Typhi ◽  
October 17 ◽  
Culture Positive ◽  
Nalidixic Acid Resistance

INTRODUCTION: Drug resistant Salmonella spp. is endemic in several Asian countries. Nalidixic acid-resistant Salmonella enterica serovar Typhi and Salmonella enterica serovar Paratyphi A show reduced susceptibility to fluoroquinolones and have resulted in a rise in treatment failures. Over the past few decades, nalidixic acid-resistant Salmonella spp have emerged in Nepal as well.MATERIAL & METHODS: This is a retrospective study that aims to provide a more recent antibiogram of S. Typhi and S. Paratyphi A isolates in Kathmandu. Between Poush, 2071 and Ashwin, 2072 (December 16, 2014 to October 17, 2015), 186 culture positive cases of enteric fever were diagnosed at the Civil Service Hospital. Upon isolation of S. Typhi or S. Paratyphi A, antimicrobial susceptibility testing was performed with amoxicillin, azithromycin, ceftriaxone, chloramphenicol, ciprofloxacin, cotrimoxazole, nalidixic acid, ofloxacin and tetracyciline.RESULTS: This study shows a much higher frequency of nalidixic acid-resistance in Kathmandu than previously reported; 95.7% in Salmonella enterica serovar Paratyphi A and 86.5% in Salmonella enterica serovar Typhi.The rates of ciprofloxacinand ofloxacin-resistance were over 50% in both serovar.CONCLUSION: In Nepal, it is necessary to reevaluate the use of fluoroquinolone therapy and introduce feasible alternatives so as to curb treatment failures.Journal of Universal College of Medical Sciences (2017) Vol. 5, No, 2, Page: 22-25

scholarly journals Suitable Disk Antimicrobial Susceptibility Breakpoints Defining Salmonella enterica Serovar Typhi Isolates with Reduced Susceptibility to Fluoroquinolones

2010 ◽  
Vol 54 (12) ◽  
pp. 5201-5208 ◽  
Author(s):  
Christopher M. Parry ◽  
Chau Tran Thuy ◽  
Sabina Dongol ◽  
Abhilasha Karkey ◽  
Ha Vinh ◽  
...  
Keyword(s):  
Nalidixic Acid ◽  
Salmonella Enterica ◽  
Acid Resistance ◽  
Inhibition Zone ◽  
Delayed Response ◽  
Asian Countries ◽  
Zone Of Inhibition ◽  
Salmonella Enterica Serovar Typhi ◽  
Nalidixic Acid Resistance ◽  
Disk Susceptibility

ABSTRACT Infections with Salmonella enterica serovar Typhi isolates that have reduced susceptibility to ofloxacin (MIC ≥ 0.25 μg/ml) or ciprofloxacin (MIC ≥ 0.125 μg/ml) have been associated with a delayed response or clinical failure following treatment with these antimicrobials. These isolates are not detected as resistant using current disk susceptibility breakpoints. We examined 816 isolates of S. Typhi from seven Asian countries. Screening for nalidixic acid resistance (MIC ≥ 16 μg/ml) identified isolates with an ofloxacin MIC of ≥0.25 μg/ml with a sensitivity of 97.3% (253/260) and specificity of 99.3% (552/556). For isolates with a ciprofloxacin MIC of ≥0.125 μg/ml, the sensitivity was 92.9% (248/267) and specificity was 98.4% (540/549). A zone of inhibition of ≤28 mm around a 5-μg ofloxacin disc detected strains with an ofloxacin MIC of ≥0.25 μg/ml with a sensitivity of 94.6% (246/260) and specificity of 94.2% (524/556). A zone of inhibition of ≤30 mm detected isolates with a ciprofloxacin MIC of ≥0.125 μg/ml with a sensitivity of 94.0% (251/267) and specificity of 94.2% (517/549). An ofloxacin MIC of ≥0.25 μg/ml and a ciprofloxacin MIC of ≥0.125 μg/ml detected 74.5% (341/460) of isolates with an identified quinolone resistance-inducing mutation and 81.5% (331/406) of the most common mutant (carrying a serine-to-phenylalanine mutation at codon 83 in the gyrA gene). Screening for nalidixic acid resistance or ciprofloxacin and ofloxacin disk inhibition zone are suitable for detecting S. Typhi isolates with reduced fluoroquinolone susceptibility.

scholarly journals Is nalidixic acid resistance linked to clinical virulence in Salmonella enterica serovar Typhi infections?

2008 ◽  
Vol 57 (8) ◽  
pp. 1046-1048 ◽  
Author(s):  
Tamilarasu Kadhiravan ◽  
Naveet Wig ◽  
K. Renuka ◽  
Arti Kapil ◽  
Sushil K. Kabra ◽  
...  
Keyword(s):  
Nalidixic Acid ◽  
Salmonella Enterica ◽  
Acid Resistance ◽  
Salmonella Enterica Serovar Typhi ◽  
Nalidixic Acid Resistance

scholarly journals Susceptibility to patterns of ciprofloxacin among nalidixic acid-resistant Salmonella isolates collected in Banepa, Nepal from enteric fever patients

2016 ◽  
Vol 89 (2) ◽  
Author(s):  
Girija Roka ◽  
Subash Pandaya ◽  
Md. Reyad-ul Ferdous ◽  
Manson Pandey ◽  
Naba Raj Pokhrel ◽  
...  
Keyword(s):  
Nalidixic Acid ◽  
Salmonella Enterica ◽  
Enteric Fever ◽  
Inhibitory Concentration ◽  
Acid Resistance ◽  
Dilution Method ◽  
Disc Diffusion ◽  
Antimicrobial Sensitivity ◽  
Broth Dilution ◽  
Nalidixic Acid Resistance

The present study determined the susceptibility to ciprofloxacin of nalidixic acid resistant <em>Salmonella</em> (NARS) isolated from enteric fever patients at Scheer Memorial Hospital, Banepa, Nepal, from June 2012 to December 2012. The antimicrobial sensitivity to nalidixic acid and ciprofloxacin was determined using modified Kirby-Bauer disc diffusion and broth dilution method according to the guidelines of the Clinical and Laboratory Standard Institute. <em>Salmonella</em> was isolated from 34 out of 992 (3.43%) blood cultures collected during the study period, and 10 (29.4%) isolates were identified as <em>Salmonella enterica</em> serotype Typhi, while 24 (70.6%) were identified as <em>Salmonella enterica</em> serotype Paratyphi. Out of the total isolates, 31 (91.2%) were nalidixic acid-resistant <em>Salmonella</em> (NARS). Among NARS, the minimum inhibitory concentration values for ciprofloxacin ranged from 0.25 to 2 mg/L and were constantly higher than those shown by the nalidixic acid-susceptible <em>Salmonella</em>. Therefore, in typhoid <em>Salmonella</em> nalidixic acid resistance may be the indicator of decreased susceptibility to ciprofloxacin.

scholarly journals Comparision of Antibiotic Susceptility of Levofloxacin with Other Commonly Tested Antibiotics Against Salmonella Enterica Serovar (Typhi And Paratyphi A)

2014 ◽  
Vol 3 (1) ◽  
pp. 19-21
Author(s):  
A Chhetri ◽  
A Manandhar ◽  
Y Shah ◽  
RC Simkhada ◽  
R Paudyal ◽  
...  
Keyword(s):  
Nalidixic Acid ◽  
Salmonella Enterica ◽  
Antibiotic Susceptibility ◽  
Enteric Fever ◽  
Clinical Laboratory ◽  
Acid Resistance ◽  
Fluoroquinolone Resistance ◽  
Diffusion Method ◽  
Salmonella Enterica Serovar Typhi ◽  
Antibiotic Susceptibility Test

Background: Increasing antibiotic resistance of bacteria is a global problem. Fluoroquinolones are recommended as first line therapy for children and adults infected with Salmonella enterica serovar Typhi and Paratyphi A. The purpose of this study was to compare the antibiotic susceptibility pattern of different classes of antibiotics with levofloxacin from blood samples of suspected enteric fever patients visiting Birhospital, Kathmandu. Methods: Antibiotic susceptibility test was performed by Kirby-Bauerdisc diffusion method as per Clinical Laboratory Standards Institute guideline. Results: Among 50 isolates of Salmonella enterica, 39 (78%) were S.Typhi and 11 (22%) were S. Paratyphi A. All the isolates were tested against antibiotics, and all isolates were found sensitive to chloramphenicol and ceftriaxone whereas 3 isolates of S. Typhi were resistant to ciprofloxacin and 1 was resistant to levofloxacin. Fluoroquinolone resistant S. ParatyphiA was not observed. Among the 10 (20%) multi drug resistant isolates, only 1 isolate was resistant to levofloxacin which was S. Typhi. Both S.Typhi (96.7%) and S. Paratyphi A (89.4%) were resistant to Nalidixic acid. Conclusion: High level of nalidixic acid resistance and even some fluoroquinolone resistance showed that the treatment of the enteric fever cannot be relied on the fluoroquinolones. Nepal Journal of Medical Sciences | Volume 03 | Number 01 | January-June 2014 | Page 19-21 DOI: http://dx.doi.org/10.3126/njms.v3i1.10344

scholarly journals Increasing Incidence and Comparison of Nalidixic Acid-ResistantSalmonella enterica subsp. enterica Serotype Typhimurium Isolates from Humans and Animals

1999 ◽  
Vol 37 (1) ◽  
pp. 266-269 ◽  
Author(s):  
Christine Heurtin-Le Corre ◽  
Pierre-Yves Donnio ◽  
Monique Perrin ◽  
Marie-France Travert ◽  
Jean-Loup Avril
Keyword(s):  
Nalidixic Acid ◽  
Gel Electrophoresis ◽  
Salmonella Enterica ◽  
Acid Resistance ◽  
Pulsed Field Gel Electrophoresis ◽  
Banding Patterns ◽  
Pulsed Field ◽  
Animal Isolates ◽  
Nalidixic Acid Resistance

We determined the resistance to quinolone of 309 Salmonella enterica subsp. enterica serotype Typhimurium strains isolated from humans and animals (cattle, pigs, or poultry) in 1995 or 1996. Nalidixic acid resistance increased from 8.5% in 1995 to 18.6% in 1996. The highest resistance levels correlated with a mutation at Ser-83 (or Asp-82). All strains remained ciprofloxacin susceptible. Human and animal isolates were compared by pulsed-field gel electrophoresis, and the banding patterns of the human isolates most closely matched those of the bovine isolates.

scholarly journals Increase in Nalidixic Acid Resistance among Non-Typhi Salmonella enterica Isolates in the United States from 1996 to 2003

2006 ◽  
Vol 51 (1) ◽  
pp. 195-197 ◽  
Author(s):  
Jennifer E. Stevenson ◽  
Kathryn Gay ◽  
Timothy J. Barrett ◽  
Felicita Medalla ◽  
Tom M. Chiller ◽  
...  
Keyword(s):  
Public Health ◽  
United States ◽  
Nalidixic Acid ◽  
Salmonella Enterica ◽  
Susceptibility Testing ◽  
Point Mutations ◽  
Acid Resistance ◽  
The United States ◽  
Control And Prevention ◽  
Nalidixic Acid Resistance

ABSTRACT Fluoroquinolones commonly are used to treat adult Salmonella infections. Fluoroquinolone treatment has failed for persons infected with nalidixic acid-resistant Salmonella. From 1996 to 2003, state public health laboratories forwarded 12,252 non-Typhi Salmonella enterica isolates to the Centers for Disease Control and Prevention for antimicrobial susceptibility testing; 203 (1.6%) of the isolates were nalidixic acid resistant, and 14 (7%) of those were ciprofloxacin resistant. Resistance to nalidixic acid significantly increased from 0.4% in 1996 to 2.3% in 2003. All ciprofloxacin-resistant isolates had at least one point mutation in the quinolone resistance determining region (QRDR) of gyrA and did not harbor qnr or have point mutations in the QRDR of gyrB, parC, or parE. Continued surveillance of antimicrobial resistance among non-Typhi S. enterica isolates is needed to mitigate the increasing prevalence of nalidixic acid resistance.

Sign in / Sign up

Export Citation Format

Share Document